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teins, each of which have been implicat-
ed in Ras transformation of fibroblasts.
Although SPA-1 seems to be the pre-
dominant Rap1GAP in blood cell precur-
sors, it remains possible that additional
or other roles of the SPA-1 protein are
involved in the in vivo effects observed
by Ishida and colleagues. However, it
seems likely that Rap1 is central to the
effects of SPA-1 deletion since an acti-
vated Rap1 gene, when overexpressed
via retroviral transduction in primary
bone marrow cells, causes a hyper-
myeloid phenotype. These studies need
to be followed up with more phenotypic
analyses, however. An additional unre-
solved question is the role that other
Rap1GAPs might have in suppressing
tumor cell growth in other tissues. As
originally proposed by Altschuler and
Ribeiro-Neto (1998), it seems plausible
that only certain cell types are sensitive
to transformation by Rap1 signaling. Also
mysterious are the mechanisms that reg-
ulate Rap1’s ability to suppress RasGTP
activity in some contexts and deliver sig-
nals that promote growth in others.
Recent data suggest that the subcellular
localization of Rap1GAP activity deter-
mines whether RasGTP signaling is sup-
pressed by Rap1, and that the two
GTPases are normally activated in differ-
ent subcellular regions of the cell (Ohba
et al., 2003). Therefore, in some cell
types and in response to the certain
stimuli, Rap1 may suppress RasGTP
signaling and proliferation. The rules
governing the phenotypic effects of Rap1
signaling remain obscure. Some of the
answers will be found when more of
Rap1’s downstream effectors and
upstream regulators are identified, and
their biological roles can be revealed in
genetic experiments like those present-
ed by Ishida and colleagues in this issue
of Cancer Cell.
David A. Largaespada
University of Minnesota Cancer Center




Altschuler, D.L., and Ribeiro-Neto, F. (1998).
Proc. Natl. Acad. Sci. USA 95, 7475–7479.
Arai, A., Nosaka, Y., Kanda, E., Yamamoto, K.,
Miyasaka, N., and Miura, O. (2001). J. Biol.
Chem. 276, 10453–10462.
Cook, S.J., Rubinfeld, B., Albert, I., and
McCormick, F. (1993). EMBO J. 12, 3475–3485.
Dupuy, A.J., Morgan, K., von Lintig, F.C., Shen,
H., Acar, H., Hasz, D.E., Jenkins, N.A.,
Copeland, N.G., Boss, G.R., and Largaespada,
D.A. (2001). J. Biol. Chem. 276, 11804–11811.
Gutmann, D.H., Saporito-Irwin, S., DeClue, J.E.,
Wienecke, R., and Guha, A. (1997). Oncogene
15, 1611–1616.
Ishida, D., Kometani, K., Yang, H., Kakugawa, K.,
Masuda, K., Iwai, K., Suzuki, M., Itohara, S.,
Nakahata, T., Hiai, H., Kawamoto, H., Hattori, M.,
and Minato, N. (2003). Cancer Cell 4, this issue.
Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa,
Y., and Noda, M. (1989). Cell 56, 77–84.
Mitelman, F., Mertens, F., and Johansson, B.
(1997). Nat. Genet. 15, 417–474.
Ohba, Y., Kurokawa, K., and Matsuda, M. (2003).
EMBO J. 22, 859–869.
Singh, L., Gao, Q., Kumar, A., Gotoh, T., Wazer,
D.E., Band, H., Feig, L.A., and Band, V. (2003). J.
Virol. 77, 1614–1620.
Wienecke, R., Konig, A., and DeClue, J.E.
(1995). J. Biol. Chem. 270, 16409–16414.
York, R.D., Yao, H., Dillon, T., Ellig, C.L., Eckert,
S.P., McCleskey, E.W., and Stork, P.J. (1998).
Nature 392, 622–626.
Zwartkruis, F.J., Wolthuis, R.M., Nabben, N.M.,
Franke, B., and Bos, J.L. (1998). EMBO J. 17,
5905–5912.
P R E V I E W S
A generally accepted model for tumor
progression through clonal evolution is
illustrated in the left portion of Figure 1.
Evolutionary details are particularly well
worked out in colorectal cancer (Fearon
and Vogelstein, 1990). One important
prediction of the clonal progression
model is that the spectrum of aberrations
in metastatic lesions will be similar to
those in the primary tumors from which
they originated since the metastases
represent the end stage of evolution.
Karyotypic and genomic analyses of
cancers of the breast (Kuukasjarvi et al.,
1997; Pandis et al., 1998), bladder
(Hovey et al., 1998), colon (Al-Mulla et
al., 1999), and kidney (Bissig et al.,
1999) often show this feature. However,
these studies also show exceptions
where some metastases bear almost no
genomic resemblance to the primary
tumor from the same patient. Bessig et
al., for example, found that ?30% of
renal cell metastases were almost com-
pletely different from the primary tumors
in the same patients. Likewise,
Kuukasjärvi et al. (1997) found a signifi-
cant fraction of breast metastases that
were not strongly clonally related to the
primary tumors in the same patients.
They also analyzed metastases at sever-
al sites in individual patients and found
substantial evolutionary divergence
between these metastatic lesions and
the primary tumor AND between the
metastases themselves. In most cases,
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Tumor progression to metastasis usually is assumed to occur through clonal genomic and epigenetic evolution. However,
Schmidt-Kittler et al. (2003) present evidence that challenges this paradigm.They show that genomic aberrations in tumor
cells disseminated in the bone marrows of patients with no clinical evidence of metastasis generally do not resemble the
aberrations in the primary tumors from which they arose. They interpret this to mean that tumor cells disseminate very
early and evolve to metastatic disease independent from the primary tumor.Their model suggests that adjuvant therapies
should be targeted to lesions in the disseminated cells rather than lesions found in primary tumors.
CANCER CELL : JULY 2003 5
metastases showed increased
genome complexity com-
pared to the primary tumors
in the same patient. Taken
together, these studies sug-
gest the possibility illustrated
in the right part of Figure 1,
that at least for some tumors,
the cells destined to form
metastatic disease separate
relatively early from the pri-
mary tumor and evolve inde-
pendently.
Schmidt-Kittler et al.
(2003) now present evidence
that further challenges the
clonal-progression-to-metas-
tasis paradigm. Their study is
based on comprehensive
genomic analyses of primary
breast tumors and single
cytokeratin-positive (CK+)
epithelial cells from the bone
marrow of these same
patients. Patients were
selected that had no evi-
dence of metastatic disease
(UICC stage M0) or had
metastasized (UICC stage
M1). Previous publications
have shown that CK+ cells
originate in the tumor and
their presence is associated
with increased propensity to
develop metastatic disease
(Braun et al., 2000; Pantel et
al., 1999). The CK+ cells and cells from
the corresponding primary tumors were
analyzed for loss of heterozygosity and
genome copy number using comparative
genomic hybridization as described ear-
lier (Klein et al., 1999). The CK+ cells
from M0 patients showed approximately
half as many genomic aberrations as
those from M1 patients. Surprisingly,
most of the CK+ cells from M0 patients
showed little resemblance to the primary
tumors from which they presumably
arose. Schmidt-Kittler et al. reasoned
that this might be because the dissemi-
nated cells separated from the tumor
quite early—perhaps before telomere
crisis. To explore this, they compared the
genomic abnormalities in disseminated
cells from M0 and M1 patients. Cells
from M0 patients showed whole chromo-
some copy number aberrations while
cells from M1 patients showed subchro-
mosomal changes characteristic of aber-
rations that form during telomere crisis.
They attribute the eventual development
of metastatic disease in M0 patients to
these early disseminated cells. They
suggest that these cells transition
through crisis independently from cells in
the primary tumor and evolve indepen-
dently of the primary tumor. The long-
term persistence and slow evolution of
these disseminated cells would explain
why metastatic disease sometimes
develops years after apparently suc-
cessful treatment of the primary tumor.
The parallel and independent evolu-
tion model proposed by Schmidt-Kittler
et al. has important clinical implications if
it is correct. In particular, the model sug-
gests that therapies that target proper-
ties of advanced primary tumors will be
ineffective against metastatic cells that
evolved independently after early sepa-
ration from the primary tumor. Instead,
selection of adjuvant therapies should be
based on analyses of disseminated
tumor cells rather than on the primary
tumor. These cells, Schmidt-Kittler et al.
argue, will show the early genetic or epi-
genetic events that are common to the
primary tumor and metastases and thus
are optimal therapeutic tar-
gets. While currently chal-
lenging, genomic analyses
of single CK+ tumor cells are
increasingly tractable and
eventually might develop
into a routine clinical assay.
Of course, this approach to
therapy selection presumes
that the disseminated CK+
cells are viable and repre-
sentative of those that
evolve into metastatic dis-
ease. Proving this will
require much additional
work. If these cells do
spread prior to telomere cri-
sis as Schmidt-Kittler et al.
suggest, it seems likely that
most will be eliminated dur-
ing crisis. In this case,
genomic analyses of these
cells might provide little
information about the cells
that do evolve into metas-
tases. Work by Jain and col-
leagues (Swartz et al., 1999)
also argues against the via-
bility of disseminated tumor
cells. Their murine model
studies indicate that cells are
shed from tumors in large
numbers but have reduced
clonogenicity, resistance to
apoptosis, and in vivo tumori-
genicity. If true in human
patients, the disseminated cells might
have little genomic similarity to metas-
tases that eventually form.
In sum, Schmidt-Kittler et al. have
suggested the importance of selecting
therapies based on genomic analyses of
disseminated tumor cells collected at the
time of surgery. However, the true utility
of this approach remains to be proven.
Perhaps the best way to resolve this
issue is by comparing genomic signa-
tures of disseminated tumor cells taken
from M0 patients with those from
metastatic cells that arise years later.
This will be difficult, at least in the United
States, since bone marrow aspiration is
not a routine part of the staging of prima-
ry breast cancer, samples of metastatic
lesions are not routinely collected and,
the time to acquire the appropriate
matched bone marrow aspirates and
metastatic tumor lesions is long.
Acquisition of these resources will have
to be initiated immediately in order to
resolve this important issue in a timely
manner.
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Figure 1. Schematic representation of serial and parallel models of
tumor evolution to metastasis
In one model (left branch), progression to metastasis occurs through
clonal evolution so that most properties of the primary tumor will be
found in disseminated metastatic cells. Another model (right branch)
suggests that cells that form metastatic disease separate early from
the primary tumor and evolve more-or-less independently from the
primary tumor.
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